News for Pulse Biosciences, Inc. (PLSE)

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2025 Earnings Call May 8, 2025 4:30 PM ETCompany ParticipantsPhilip Taylor - Gilmartin GroupJon Skinner – CFOPaul...

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Pulse Biosciences

Exploring the innovative Nano-Pulse Stimulation technology of Pulse Biosciences Inc (PLSE).Assessing the financial health and strategic positioning of Pulse Bi

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPLSE.OQ - Pulse Biosciences IncQ1 2025 Pulse Biosciences Inc Earnings CallMay 08, 2025 / 08:30

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationâ„¢ (nanosecond PFA or nsPFAâ„¢) technol

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationâ„¢ (nanosecond PFA or nsPFAâ„¢) technol

Pulse Biosciences (PLSE) is under scrutiny following an analysis by White Diamond Research. The firm highlighted the company's Nano-Pulse Stimulation technology

White Diamond Research has expressed skepticism regarding Pulse Biosciences' (PLSE) Nano-Pulse Stimulation technology, highlighting a series of past commercial

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationâ„¢ (nanosecond PFA or nsPFAâ„¢) technol

Summary Pulse Biosciences Inc (PLSE), a leader in bioelectric medicine, announced on April 21, 2025, that its Compensation Committee has granted equity awards t

See how Pulse Biosciences, Inc.'s stock surged 100% despite no clear commercialization timeline, management turnover, and scarce coverage. Click to read more on PLSE.

Despite promising technology and FDA clearances, Pulse Biosciences lacks a revenue stream and remains in the testing phase with no commercialized products. Read why PLSE is a hold.

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. ( CRVS), a clinical-stage biopharmaceutical company, announced to

**media[590863]**

Operator: Thank you for standing by. My name is Louella, and I will be your conference operator today.

On March 28, 2025, Pulse Biosciences Inc (PLSE) released its 8-K filing, detailing the company's financial performance for the fourth quarter and full year endi

Total GAAP Costs and Expenses: Increased by $7.7 million to $20.3 million in Q4 2024 compared to $12.5 million in the prior year period.Non-Cash Stock-Based Co

Mar 27, 2025 / 08:30PM GMTOperator Thank you for standing by. My name is Malia, and I will be your conference operator today. At this time, I would like to welc

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsPhilip Trip Taylor - Investor...